Biotechnology

Wantai Biological

Wantai Biological released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 523.34 M, actual EPS CNY -0.03

Wantai Biological to Release FY2026 Q1 Earnings on April 28 During-Market BJT

Wantai Biological released FY2025 earnings on April 20 After-Market (BJT), actual revenue CNY 1.819 B (forecast CNY 2.059 B), actual EPS CNY -0.31 (forecast CNY -0.1808)

Wantai Biological released FY2025 Q4 earnings on April 20 After-Market (BJT), actual revenue CNY 320.6 M, actual EPS CNY -0.158

Wantai Biological to Release FY2025 Earnings on April 21 After-Market (BJT), Forecast Revenue CNY 2.059 B, EPS CNY -0.1808

Wantai Biological released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 1.498 B, actual EPS CNY -0.137

Wantai Biological released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 654.81 M, actual EPS CNY -0.0267

Wantai Biological FY2025 Q3 Earnings Release on October 30 After-Market BJT

Wantai Biological released FY2025 Q2 earnings on August 20 During-Market (BJT), actual revenue CNY 442.94 M, actual EPS CNY -0.0702

Wantai Biological released FY2025 Semi-Annual earnings on August 20 During-Market (BJT), actual revenue CNY 843.56 M, actual EPS CNY -0.11

Wantai Biological to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

Nongfu Spring's Stock Climbs While WanTai Bio's Performance Slumps

WanTai Bio introduces nucleic acid test kits

WanTai Biological Expects a Loss of 130 to 160 Million Yuan in H1 2023

WanTai Bio Advances International Market Access for Nine-Valent HPV Vaccine

WanTai Bio expects significant decline in net profit for the first half of 2025

WanTai Bio Publishes Pricing for Domestic 9-valent HPV Vaccine

WanTai Bio Promotes Nine-Valent HPV Vaccine Procurement and WHO PQ Certification

WanTai Bio-Pharmaceutical Underwent a Large Block Trade

Wan tai Biologics Launched a Series of Neurological Disease Diagnostic Products

300142

688185

06185

603392

The United States plans to adjust its childhood vaccination schedule, removing universal recommendations for several vaccines, which will take effect immediately, bringing the U.S. vaccination program closer to the simplified Danish childhood vaccination schedule. According to the new plan, the Centers for Disease Control and Prevention (CDC) recommends vaccinations for 11 diseases, whereas the previous guidelines recommended vaccinations for 17 diseases. The CDC advises that parents and healthcare providers jointly decide whether to vaccinate against rotavirus, COVID-19, influenza, meningococcal disease, hepatitis A, and hepatitis B

AASTOCKS

WALVAX

CanSinoBIO

CANSINOBIO

The U.S. Centers for Disease Control and Prevention simplifies the childhood vaccination schedule

According to data from healthcare research firm 3 Axis Advisors, despite facing price reduction pressures from the U.S. government, pharmaceutical companies plan to raise the prices of at least 350 drugs next year, with an average increase of 4%. These drugs include COVID-19 vaccines, respiratory syncytial virus vaccines, shingles vaccines, and the blockbuster cancer treatment Ibrance. Compared to last year, the number of drug price increases planned for 2026 has increased, with over 250 drugs announced for price hikes last year

According to reports, pharmaceutical companies will raise the prices of 350 drugs in the United States next year, with an average increase of 4%

399401

Tonix Pharmaceuticals Holdings (TNXP.US) showed a significant surge in trading volume yesterday, with the previously stagnant small-cap pharmaceutical stocks experiencing a return of institutional investors, and community FOMO sentiment gradually rising. The stock price broke through short-term moving average resistance, igniting trading enthusiasm in the morning session, as bulls attempted to dominate the market. Although there are currently no major favorable policies in the pharmaceutical industry, speculation surrounding vaccine development and industry policy adjustments has resurfaced, transmitting to the small-cap biotech sector, where capital competition is rapidly heating up. Institutions quickly built positions and lifted prices in the low volatility zone, raising short-term attention. Technically, the daily K-line formed a large bullish candle, breaking through the upper band of the moving average system, with the MACD indicator also turning upward. The main funds made three upward pushes in intraday trading, with sufficient follow-up capital, indicating strong momentum. Today, attention should be paid to whether the gentle increase in volume can be sustained. If the short-term enthusiasm for chasing prices continues, it may ignite a rally in small-cap pharmaceutical stocks. Caution is needed against potential follow-up buying failing to sustain, which could lead to a quick cooling of the market as institutions take profits. For right-side traders, Tonix's intraday volatility today is an important signal for the initiation of a rebound trend

Technical Forecast

CNI Mid-Small Cap.

Morning Trend | Tonix Pharmaceuticals Holding experiences significant intraday volatility, is a rebound trend about to start?

Sinovac has signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese vaccine company to win the bid for this project. Sinovac will collaborate with Brazil's Tecpar Institute and Eurofarma to provide approximately 60 million doses of varicella and rabies vaccines to Brazil over the next ten years, with a contract amount exceeding 700 million USD, setting a record for the largest international order for a Chinese vaccine company

Wallstreetcn

Sinovac: Signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, creating the largest international order for Chinese vaccines

Kangtai Biological announced that its developed quadrivalent influenza virus split vaccine has completed preparations for Phase I clinical trials, which have now commenced, and the first subject has been successfully enrolled. The vaccine is suitable for individuals aged 6 to 35 months and aims to stimulate immunity to prevent influenza virus. The trial employs a single-center, randomized, blind, positive control design to evaluate the vaccine's safety and preliminary immunogenicity

Zhitong

Kangtai Biological: Quadrivalent Influenza Virus Split Vaccine Starts Phase I Clinical Trial

600201

603566

300119

Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

JINYU

PULIKE

RINGPU

Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

Recently, reporters conducted research in Nanjing, Shenzhen, Chengdu, and other places and found that the flu vaccine vaccination wave has arrived this year. The number of people getting vaccinated at community hospitals has increased, leading to some vaccination sites having "appointments but no vaccines." The types of vaccines administered are mainly domestic vaccines. In terms of price, since the beginning of the year, the government procurement price of the trivalent vaccine has continued to decline, even reaching a "floor price" of 5.5 yuan per dose, while the price of the self-paid quadrivalent vaccine has remained stable this year

Some vaccination sites for the flu vaccine have "appointments but no vaccines," with price trends for different tiers of vaccines diverging

Wantai Biological announced that it will hold an extraordinary shareholders' meeting on October 31, 2025, to review the proposal to change the use of 729,970 shares repurchased and to cancel them. The intended use of the repurchased shares will be changed from "for employee stock ownership plans or equity incentives" to "for cancellation and reduction of registered capital." After the cancellation, the company's total share capital will be reduced from 1,265,122,774 shares to 1,264,392,804 shares, and this matter will not have a significant impact on the company's finances

Wantai Biological: Plans to change the use of 729,970 repurchased shares and cancel them

Wantai Biological(603392.SH)